<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098838</url>
  </required_header>
  <id_info>
    <org_study_id>CLCL161A2101</org_study_id>
    <nct_id>NCT01098838</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of LCL161 in Patients With Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Dose-escalation Study of Oral LCL161 in Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid
      tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated
      dose of LCL161.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and type of adverse events</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of amount of LCL161 that gets into blood stream from tablet formulation versus liquid formulation (bioavailability)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood assessments to determine how much LCL161 gets into the blood stream (pharmacokinetic parameters)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measurements to determine how LCL161 interacts with proteins related to cancer such as cIAP, cytokines, and cell death markers; hair, skin and tumor samples will be evaluated for target inhibition</measure>
    <time_frame>Intermittent throughout treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solid tumor response criteria will be used to identify any anti-tumor activity</measure>
    <time_frame>After a minimum of 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Weekly dosing of LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>by mouth (oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison of LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet versus liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily dosing of LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>by mouth for 4 days followed by a 3-day rest period every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCL161</intervention_name>
    <arm_group_label>Weekly dosing of LCL161</arm_group_label>
    <arm_group_label>Comparison of LCL161</arm_group_label>
    <arm_group_label>Twice daily dosing of LCL161</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid tumor

          -  ECOG performance status 0-2

          -  Life expectancy greater than or equal to 12 weeks

          -  Must meet certain blood laboratory values

          -  Must meet criteria for time since the last dose of prior therapy

          -  Must provide written informed consent to participate in this study

        Exclusion Criteria:

          -  Active and/or symptomatic brain tumors or brain metastases.

          -  Patients with unresolved nausea, vomiting, or diarrhea

          -  Any ongoing severe and/or uncontrolled medical condition that could compromise
             participation in the study including heart, lung or inflammatory disease

          -  Any disease that may significantly alter the absorption of the study drug (for
             example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption
             syndrome, or removal of small bowel)

          -  Patients who are currently receiving treatment with steroids at a certain dose or
             other immunosuppressive treatment that cannot be stopped prior to starting study drug

          -  Patients who are currently receiving treatment with certain medications

          -  Patients who have received radiation therapy or have undergone major surgery within
             the last 4 weeks

          -  Women of child-bearing potential who are pregnant or breast feeding.

          -  Known diagnosis of human immunodeficiency virus (HIV) infection or chronic active
             hepatitis B or C

          -  Patients unwilling or unable to follow the protocol

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC/ Lineberger Comprehensive Cancer Center Dept. of LinbergerCancerCtr(2)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.NovartisClinicalTrials.com</url>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>adults</keyword>
  <keyword>solid tumor</keyword>
  <keyword>apoptosis</keyword>
  <keyword>programmed cell death</keyword>
  <keyword>LCL161</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

